CARLSBAD, Calif.--(BUSINESS WIRE)--ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today enrollment in the ongoing ArtVentive EOS™ Endoluminal Occlusion System, OCCLUDE post-market surveillance study.
The study is dedicated to further advancement of use of the ArtVentive EOS™ embolization device in treating venous and arterial cases where the precise placement and immediate, efficient vessel embolization are paramount.
The study is dedicated to further advancement of use of the ArtVentive EOS™ embolization device in treating venous and arterial cases where the precise placement and immediate, efficient vessel embolization are paramount.
